CTL07-II is a healthy feeder-free and characterized human induced pluripotent stem (iPS) cell line. Cultured under xeno-free and defined conditions. The line is generated from healthy human fibroblasts with nonintegrating Sendai virus vectors encoding the four Yamanaka factors, OCT4, SOX2, KLF4 and cMYC. The generated iPS cells are free from reprogramming vectors and their purity, karyotypic stability and pluripotent capacity is confirmed.
Resource details
• Cell authentication analysis confirmed that human iPS cell line, CTL07-II is genetically identical to the original fibroblasts. A total of 15 alleles and gender-determining marker was used. Result in Fig. 1A .
• Human iPS cell line, CTL07-II display characteristic human iPS cell phenotype with large nucleus-to-cytoplasmic ratio, prominent nucleoli and defined bright cell borders. The iPS cells grow in monolayers with tight connections. Fig. 1B .
• Human iPS cell line, CTL07-II is free from reprogramming vectors.
Confirmed with RT-PCR using Sendai-virus vector specific primers. Result in Fig. 1C .
• Human iPS cell line, CTL07-II is karyotypically normal 46 XY, analyzed by Giemsa banding, Fig. 1D .
• Human iPS cell line, CTL07-II expresses pluripotency-associated genes confirmed at mRNA level by RT-PCR and by RNA-expression array and at protein level by immunocytochemistry. Fig. 1E -H.
• Purity of the line was controlled by Cell authentication (Fig. 1A) and by immunocytochemistry demonstrating that all cells express the nuclear pluripotency associated markers OCT4 and NANOG ( Fig. 1G-H ).
• Human iPS cell line, CTL07-II displayed pluripotent capacity, confirmed by embryonic formation assay. RT-PCR detected presence of mesodermal, endodermal and ectodermal markers. 
Materials and methods

Culture conditions
Fibroblast medium: IMDM, Life technologies, cat no: 2198002-032, 10% Fetal bovine serum, Invitrogen, cat no: 10270106, 1% Penicillinstreptomycin, Life Technologies, cat no: 15070-063. iPS cell medium: Essential 8™ medium, ThermoFisher Scientific, cat nr: A1517001. iPS cell coating during derivation and expansion was human recombinant Laminin-521, Biolamina, cat no: LN521-03. iPS Stem Cell Research 17 (2016) iPS cell clones appeared around 3 weeks post transduction, these were manually picked and expanded clonally in defined and xeno-free conditions see culture conditions se culture conditions.
Cell authentication
AmpFISTER@Identifiler, Applied Biosystems, cat no: 4322288. Performed at the Forensic department in Linköping, Sweden. Cell pellets were collected at fibroblast stages and at established iPS cell stages.
RT-PCR
mRNA extraction using Qiagen RNeasy mini kit cat no: 74,106 with additional DNase I treatment, RNase-Free DNase set, Qiagen, cat no: 79,254. Total cDNA was produced by SuperScript III First Strand kit containing RNaseH, Invitrogen cat no: 18080051, on 500 ng of total mRNA. GAPDH F AGGTCGGAGTCAACGGATTTG, GAPDH R GTGATGGCATG GACTGTGGT.
Primers for loss of Sendai vectors: SeV F GGATCACTAGGTGATATCG AGC, SeV R ACCAGACAAGAGTTTAAGAGATATGTATC, Klf4 SeV F TTCC TGCATGCCAGAGGAGCCC, Klf4 SeV R AATGTATCGAAGGTGCTCAA, cMyc SeV F TAACTGACTAGCAGGCTTGTCG, cMyc SeV R TCCACATACAG TCCTGGATGATGATG.
Primers for pluripotency factors: NANOG F CATGAGTGTGGATCCA GCTTG, NANOG R CCTGAATAAGCAGATCCATGG, OCT4 F CTCACCCTG GGGGTTCTATT, OCT4 R CTCCAGGTTGCCTCTCACTC.
RT-PCR for detection of remaining Sendai vectors was performed on 500 ng of total cDNA and at 32 PCR cycles. RT-PCR for pluripotency factors and germ layer specific markers were performed on 500 ng of total cDNA and a total of 30 PCR cycles. Control was GAPDH for all the RT-PCR analyses.
Test for Loss-of Sendai vector and expression of pluripotency markers was performed at passage 12.
Primers for mesoderm: HAND1 F CATCACCAATGAACCTCGTG, HAND1 R GCAGGGAAGTCAGGACCATAG, RUNX1 F CCCTAGGGGATGTT CCAGAT, RUNX1 R TGAAGCTTTTCCCTCTTCCA, Primers for ectoderm: N-CAM F ATGGAAACTCTATTAAAGTGAACCTG, N-CAM R TAGACCTCA TACTCAGCATTCCAGT, NESTIN F CTGCTACCCTTGAGACACCTG, NESTIN R GGGCTCTGATCTCTGCATCTAC, primers for endoderm: AFP F AGCTTG GTGGTGGATGAAAC, AFP R CCCTCTTCAGCAAAGCAGAC, GATA4 F CTAG ACCGTGGGTTTTGCAT, GATA4 R TGGGTTAAGTGCCCCTGTAG.
DNA ladder: GeneRuler™ 100 bp DNA ladder, Invitrogen cat no: 150,628,050. (Hovatta, 2003) . Result from expression array Illumina HumanHT-12 v4 BeadChip. G) Immunocytochemistry on CTL07-II for pluripotnecy markers, OCT4 and TRA1-81. H) Immunocytochemistry on CTL07-II for pluripotnecy markers, NANOG and TRA1-60. I) Bright field picture of free-floating embryonic bodies at day 5 of differentiation. J) RTPCRanalysis of embryonic bodies at day 21 of differentiation. From left; DNA ladder, alpha-feto protein, GATA4 (mesoderm), HAND1, RUNX1 (mesoderm) and N-CAM, NESTIN (ectoderm), GAPDH and GAPDH without template, DNA ladder. K) PluriTest result, Novelty score. From left: human iPS cell line CTL07-II, human ES cell line hESC 181, Fibroblasts CTL03. Green indicates that the expression pattern is similar to pluripotent cells and red indicates mismatch in expression pattern. Both human iPS cell line CTL07-II and the human ES cell line hESC 181 were found pluripotent. Novelty score for CTL07-II was: 1,58. L) Model-Based multi-Class Pluripotency score. Based on all samples in the stem cell model matrix. From left human iPS cell line CTL07-II, human ES cell line hESC 181, human fibroblasts CTL03. Pluripotency score for CTL07-II was: 23,27.
